Koninklijke Philips (PHIA) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
13 Apr, 2026Strategic direction and growth ambitions
Entering a new phase focused on profitable growth, targeting mid-single-digit sales CAGR and mid-teens margins by 2028, with €4.5–5 billion cumulative cash generation over the period.
Strategy built on three pillars: focused value creation by segment, innovation growth leveraging AI and platforms, and disciplined execution with commercial excellence.
Segment-specific strategies emphasize organic and inorganic investments, especially in Interventional and Monitoring platforms, with North America as a core growth engine.
ESG ambitions for 2030 include improving 2.5 billion lives, significant emissions reductions, and embedding sustainability in business models.
China and other growth markets remain long-term opportunities, with a disciplined approach to capital allocation and innovation tailored to local needs.
Innovation and platform leadership
Accelerated innovation pipeline, including world-firsts in imaging (helium-free 3T MRI), AI-native interventional platforms (Azurion AI), and new care intelligence platforms in monitoring.
Platform-based approach integrates hardware, software, data, and AI, leveraging a global installed base of 2.5 million systems and reaching 80% of top hospitals.
Partnerships with leading clinical and technology organizations (e.g., Mayo Clinic, AWS, NVIDIA) drive co-creation and speed to market.
AI and data orchestration are central to future growth, enabling personalized, efficient, and scalable care across hospital and home settings.
Innovation expected to contribute 70–100 bps to growth acceleration, with commercial excellence adding 40–70 bps.
Financial framework and capital allocation
Achieved 3.1% sales CAGR and expanded Adjusted EBITA margin from 7.4% in 2022 to 12.3% in 2025, with positive cash generation and a robust balance sheet.
Targeting 3–4.5% sales growth in 2026, stepping up to mid-single-digit CAGR through 2028, with margin expansion from 12% to mid-teens.
Free cash flow target of €1.3–1.5 billion in 2026 and €4.5–5 billion cumulatively, supported by productivity programs and working capital optimization.
€1.5 billion new productivity program focused on cost competitiveness, lean central functions, and AI-driven efficiency.
Capital allocation priorities: organic growth (R&D, CapEx), stable dividend (40–50% payout), selective M&A, and periodic share buybacks.
Latest events from Koninklijke Philips
- Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - All AGM proposals passed, with focus on profitability, ESG, and resilience amid global risks.PHIA
AGM 20253 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026 - AI-driven health innovation and open platforms fuel growth and ESG leadership.PHIA
Show & Tell 202420 Jan 2026 - Strong margin gains offset flat sales and China weakness, with robust operational performance.PHIA
Q3 202418 Jan 2026 - 2024 saw margin gains, strong cash flow, and finalized US Respironics settlements despite China declines.PHIA
Q4 20248 Jan 2026 - Sales fell 2% but order intake and net income improved; margin guidance cut on tariffs.PHIA
Q1 202524 Nov 2025 - Margin up 130 bps to 12.4% on 1% sales growth and strong order intake; guidance raised.PHIA
Q2 20255 Nov 2025 - Q3 2025 saw 8% order growth, 3% sales growth, and margin expansion, with strong cash flow.PHIA
Q3 20254 Nov 2025